The DOI matches its Crossref record.
Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Abstract
European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas. In a phase II trial of ifosfamide 2.0g/m2 days 1 to 4 with mesna uroprotection in 124 patients with previously failed sarcomas, four (3%) responded completely (95% exact confidence interval, 1% to 8%) and 26 (21%) had a complete or partial response (95% exact confidence interval, 14% to 29%). The median time to progression was 5 and 9 months for partial and complete responders, respectively. In the subset of soft tissue sarcomas, the response rate for the patients receiving bolus administration was 26%, compared with 9% for the patients receiving a continuous infusion schedule (P = .03). The response rates among patients with soft tissue and bony sarcomas with a performance score of 0-2 and 0-1 prior to chemotherapy administration were 20% and 40%, respectively. Somnolence or confusion developed in 19%. Neurotoxicity was significantly associated with poor performance status (P less than .01), elevated creatinine (P less than .01), and low bicarbonate levels (P = .05). A serum bicarbonate less than 20 developed in 31% of the patients and was significantly associated with older age (P = .01), elevated creatinine (P = .02), and female sex (P = .06). Hematuria was significantly associated with no uroprotection (the first four patients did not receive mesna because it was unavailable), but was not associated with prior cyclophosphamide, pelvic radiotherapy, age, or bolus v continuation infusion schedule. Thus, ifosfamide is active in failed sarcomas and warrants further study in previously untreated patients with sarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J. H., Pritchard, D. J., Gebhardt, M. C., Dickman, P. S., Perlman, E. J., Meyers, P. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020890 · Cited by 1,328
Self-citationChemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Anninga, J. K., Gelderblom, H., Fiocco, M., Kroep, J. R., Taminiau, A. H. M., Hogendoorn, P. C. W., & Egeler, R. M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.030 · Cited by 456
Stein, B. N., Petrelli, N. J., Douglass, H. O., Driscoll, D. L., Arcangeli, G., & Meropol, N. J. (1995) · Cancer · doi:10.1002/1097-0142(19950101)75:1<11::aid-cncr2820750104>3.0.co;2-n · Cited by 271
Patel, S. R., Vadhan-Raj, S., Papadopolous, N., Plager, C., Burgess, M. A., Hays, C., & Benjamin, R. S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2378 · Cited by 257
Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines.
Lewin, J., Puri, A., Quek, R., Ngan, R., Alcasabas, A. P., Wood, D., & Thomas, D. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70475-3 · Cited by 44
Metadata
- Authors
- Antman, K. H., Ryan, L., Elias, A., Sherman, D., & Grier, H. E.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-01
- Volume
- 7
- Issue
- 1
- Pages
- 126-131
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153365867
- Cited by
- 241
- References
- 0
- FWCI
- 19.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. https://app.cochat.ai/papers/10.1200/jco.1989.7.1.126
- The paper
- Antman, K. H., Ryan, L., Elias, A., Sherman, D., & Grier, H. E. (1989). Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1989.7.1.126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.